Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.
OBJECTIVE
To determine if 6 months of neo-adjuvant androgen deprivation is associated with the long-term risk of cardiac mortality.


METHODS
In the TROG 96.01 trial, 802 men with locally advanced prostate cancer were randomized to radiotherapy either alone or with 3 or 6 months of neo-adjuvant androgen deprivation therapy (NADT). Competing risk methodology was used to derive the cumulative incidence of fatal cardiac events.


RESULTS
At 10 years, the cumulative incidence of fatal cardiac events for the radiation therapy alone arm was 7.54% compared to a nonstatistically significant decreased incidence of 6.44% in the 6-month NADT arm (p = 0.65). Men aged over 65 years were not at an increased risk. Additional androgen deprivation therapy given as secondary treatment at tumor progression did not confer an increased risk.


CONCLUSIONS
These data suggest that fatal cardiac events are not more common in men receiving up to 6 months of NADT.
School of Medicine and Public Health, The University of Newcastle, Callaghan, N.S.W., Australia.
Chantelle
C
Wilcox
Allison
A
Kautto
Allison
A
Steigler
James W
JW
Denham
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality*; D015897:Comorbidity; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D011878:Radiotherapy / Q000379:methods; D012306:Risk; D013997:Time Factors
D000726:Androgen Antagonists; D000728:Androgens